ADCT Latest Press Releases

-- October 8, 2026 --

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements PRNewswire 9:01 AM

-- September 3, 2026 --

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference PRNewswire 7:15 AM

-- August 13, 2026 --

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates PRNewswire 7:30 AM

-- August 6, 2026 --

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 PRNewswire 7:30 AM

-- July 1, 2026 --

ADC Therapeutics Announces New Employee Inducement Grant PRNewswire 4:05 PM

-- June 30, 2026 --

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial PRNewswire 7:15 AM

-- June 24, 2026 --

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities PRNewswire 7:31 AM

-- June 23, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT Globe Newswire 5:50 PM

-- June 18, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PRNewswire 10:02 AM

-- June 16, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA - ADCT Globe Newswire 5:36 PM

-- June 11, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PRNewswire 10:01 AM

-- June 9, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT Globe Newswire 1:20 PM

-- June 3, 2026 --

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma PRNewswire 4:05 PM

Market Data Delayed 15 Minutes